Identifying clinical features associated with electroconvulsive therapy response in adolescents with major depressive disorder using machine learning

BackgroundElectroconvulsive therapy (ECT) is an effective treatment for adolescent major depressive disorder (MDD), but its efficacy varies. This study utilized machine learning (ML) to identify baseline clinical factors associated with poor ECT response.MethodsWe retrospectively enrolled 503 adolescent MDD patients. A poor response was defined as a <50% reduction on the Hamilton Depression Scale (HAMD-24). The optimal ML algorithm (Random Forest, RF) was selected from nine candidates and then simplified using recursive feature elimination (RFE) and interpreted via Shapley Additive Explanations (SHAP).ResultsA simplified model using two baseline features—the neutrophil-to-platelet ratio (NPR) and pre-treatment HAMD score—achieved an AUC of 0.731 on the testing set, comparable to the full-feature model (AUC: 0.751). SHAP analysis revealed that a lower baseline NPR and a lower pre-treatment HAMD score were associated with a poor response. Furthermore, retrospective statistical comparisons revealed that patients in the poor response group completed significantly fewer ECT sessions than those in the good response group.ConclusionsWe developed a concise explanatory model demonstrating that routine clinical data available at admission (blood NPR and HAMD score) can effectively stratify the risk of poor ECT efficacy. Crucially, identifying these high-risk patients early empowers clinicians to implement targeted management, ensuring they complete a full and adequate course of ECT to maximize therapeutic benefits and prevent premature termination.
<![CDATA[Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.]]>
<![CDATA[New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.]]>
<![CDATA[FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.]]>

[Articles] Who receives psychiatry-focused pharmacogenomic testing, and is it associated with prescribing patterns and acute care utilisation in depression? Real-world evidence from a large health system

In routine clinical practice, PGx testing is preferentially used in youth and adults with clinically complex histories and is associated with shifts in antidepressant prescribing patterns. Exploratory findings suggest hypothesis-generating signals of reduced psychiatric ED utilisation among patients with higher psychiatric complexity, which requires further confirmation. Observed racial disparities highlight the need for earlier and more equitable implementation. Prospective studies incorporating symptom-level and safety outcomes are needed to determine whether PGx-guided prescribing translates into meaningful clinical benefit.

Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy

Conditions: Opioid-Induced Respiratory Depression; Postoperative Complications (Cardiopulmonary); Respiratory Complications Due to Anesthesia

Interventions: Device: Infrared Pupillometry

Sponsors: NeurOptics Inc; National Institute on Drug Abuse (NIDA); University of Pittsburgh Medical Center; University of California, San Francisco

Not yet recruiting

Allopurinol in Depression

Conditions: Depression

Interventions: Drug: Sertraline 50 MG; Drug: Allopurinol 300 MG

Sponsors: Tanta University

Not yet recruiting

tDCS: Sleep to Mood in Depression (S2M-D)

Conditions: Major Depressive Disorder; MDD; Depression; Major Depressive Episode

Interventions: Device: transcranial direct current stimulation (tDCS)

Sponsors: NYU Langone Health; Zabara Foundation

Not yet recruiting